Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Enterprise Value for 8 consecutive years, with -$650.9 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value fell 40.54% year-over-year to -$650.9 million; the TTM value through Mar 2026 reached -$650.9 million, down 40.54%, while the annual FY2025 figure was -$848.3 million, 73.56% down from the prior year.
  • Enterprise Value hit -$650.9 million in Q1 2026 for Kymera Therapeutics, up from -$848.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$33.7 million in Q1 2022 and bottomed at -$848.3 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$452.9 million, with a median of -$481.9 million recorded in 2022.
  • Year-over-year, Enterprise Value soared 89.89% in 2022 and then plummeted 1076.52% in 2023.
  • Kymera Therapeutics' Enterprise Value stood at -$407.2 million in 2022, then grew by 7.93% to -$374.9 million in 2023, then tumbled by 30.37% to -$488.7 million in 2024, then plummeted by 73.56% to -$848.3 million in 2025, then grew by 23.26% to -$650.9 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$650.9 million, -$848.3 million, and -$505.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.